Cipla Limited

NSE: CIPLA

Pharma Pharmaceuticals

₹1,386

+0.65%EOD · 11 Jun

Mumbai-based generics company known for humanitarian pricing — first to offer antiretroviral HIV drugs at 1% of Western cost. Strong in respiratory, anti-infectives, and oncology.

Market Cap

₹1.11 L Cr

52W Range

₹1673 / ₹1166

Volume

454K

1Y Return

-8.6%

P/E Ratio

29.2

P/B Ratio

3.4

ROE

11.7%

Debt / Equity

1.78

Peers in Pharma

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Cipla Limited(this stock)	₹1,386	₹1.11 L Cr	29.2	3.4	11.7%	0.93%
Sun Pharmaceutical Industries LimitedSUNPHARMA	₹1,796.6	₹4.29 L Cr	37.3	5.1	14.7%	0.93%
Dr. Reddy's Laboratories LimitedDRREDDY	₹1,277	₹1.06 L Cr	24.9	2.8	11.8%	0.63%
Lupin LimitedLUPIN	₹2,281.4	₹1.03 L Cr	19.5	4.6	26.9%	0.53%

Technical Indicators

Full analysis · objective math, not advice

Returns

+0.7%

-1.1%

-2.8%

+13.4%

-7.4%

-8.6%

Weinstein Stage

Stage 4 — Declining (downtrend)

RSI (14)

35 Neutral

Trend Template

2/7weak

Moving Averages (price vs MA)

20-DMA

₹1397

below

50-DMA

₹1357

above

150-DMA

₹1374

above

200-DMA

₹1416

below

From 52W High

-17.2%

From 52W Low

+18.9%

Support (20D)

₹1354

Resistance (20D)

₹1432

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+5.9% CAGR

Up 7 of last 11 years

Earnings Quality

Mostly cash-backed

OCF / Net Profit = 0.81x · 12/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.